Emerging therapies offer hope for improved gastric cancer survival

Gastric cancer poses a significant global health challenge, with nearly 1 million new cases and over 650,000 deaths annually. The disease shows geographical disparities and a troubling rise in early-onset cases among those under 50. Key risk factors include H. pylori infection and unhealthy lifestyles. While standard treatments include surgical resection and chemotherapy, advancements in minimally invasive techniques and emerging therapies like immunotherapies signal a new era in management, focusing on better survival and quality of life.